AUTHORS
Jelien den Hollander, PharmD, Robert F. Sidonio Jr, MD,MSc2, Marjon H. Cnossen, MD, PhD3, Ron A. A. Mathôt, PhD4
AFFILIATIONS
1 Amsterdam University Medical Centre, Amsterdam, Netherlands
2 Emory University School of Medicine, Atlanta, United States
3 Erasmus MC Sophia Children’s Hospital, Rotterdam, Netherlands
4 Amsterdam University Medical Centre, Amsterdam, Netherlands
ABSTRACT
Background: Pharmacokinetic (PK)-guided dosing with plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII) concentrate in a ratio of 1:1 (Wilate®) is an attractive strategy to individualize prophylactic treatment of von Willebrand disease (VWD), given the wide interindividual variability in breakthrough bleeding and PK. However, the appropriate PK metric and corresponding VWF/FVIII targets to guide dose adjustments remain unclear. This reflects the heterogeneity of VWD types, encompassing quantitative and qualitative defects, with varying residual endogenous VWF and FVIII activities, making it inherently difficult to identify a single PK metric applicable to all patients.
Aim: Assess the applicability of different PK metrics for PK-guided dosing of prophylaxis with pdVWF/FVIII (1:1) in patients with VWD.
Methods: Individual PK parameters for VWF ristocetin cofactor activity (VWF:RCo) and FVIII coagulant activity (FVIII:C) were estimated from patients enrolled in the WIL-31 trial (NCT04052698) using a two-compartmental population PK model. For each patient, VWF:RCo and FVIII:C PK curves were simulated under three prophylactic regimens: 30 IU/kg twice weekly (reference), 60 IU/kg twice weekly (dose increase), and 30 IU/kg three times weekly (frequency increase). Three PK metrics were evaluated for both VWF:RCo and FVIII:C across regimens: trough levels, exogenous area under the curve (AUCexo; drug effect only) and total area under the curve (AUCtotal; endogenous activity and drug effect combined).
Results: Simulations revealed that the response to dose or frequency escalation varied between the 31 patients, driven by differences in individual clearance (CL) and endogenous activity of VWF:RCo and FVIII:C. Here, we highlight three interesting cases.
Patient 1 (55 y, 48 kg, VWD type 3) exhibited a relatively high VWF:RCo CL (2.4 dL/h) and a low FVIII:C CL (0.5 dL/h). Doubling the dose resulted in a modest increase in VWF:RCo trough (+0.3-0.6 IU/dL), whereas FVIII:C trough increased substantially (+8.6–13.5 IU/dL). AUCexo and AUCtotal increased by approximately 95–100% for both VWF:RCo and FVIII:C. Increasing dosing frequency similarly failed to raise VWF:RCo trough meaningfully (+0.4–1.2 IU/dL), despite an increase in AUCexo and AUCtotal of 40–50%.
Patient 2 (52 y, 112 kg, VWD type 3) had extremely high CL of both VWF:RCo and FVIII:C, with respective values of 8.5 and 3.6 dL/h. Doubling the dose and increasing the frequency resulted in a marginal increase for troughs of both VWF:RCo (+0.1–0.2 and +0.2–0.4 IU/dL) and FVIII:C (+0.1–0.4 and +0.4–2.2 IU/dL). In contrast, AUCexo and AUCtotal increased substantially (VWF:RCo: 96% and 73%, FVIII:C 100% and 88%) for both components upon doubling the dose.
Patient 3 (9 y, 41 kg, VWD type 1) had endogenous VWF:RCo and FVIII:C activity (10.6 and 45.6 IU/dL) and CL (2.1 and 2.1 dL/h). Both trough and AUCtotal levels were largely determined by endogenous activity. Doubling the dose increased VWF:RCo AUCtotal by only 39% and FVIII:C AUCtotal by 11%, with negligible trough changes for both components (≤0.5 IU/dL), while AUCexo increased proportionally (99% and 94%) to dose.
Conclusion: These simulations demonstrate that specific PK metrics should be used when monitoring treatment with pdVWF/FVIII (1:1) in VWD patients depending on a patient’s clearance and endogenous levels. We have shown that trough levels are informative when CL was low to moderate and endogenous activity was low. AUCtotal provides a comprehensive picture of overall hemostatic exposure but is only useful for treatment guidance when endogenous activity is negligible, irrespective of a patient’s CL. AUCexo is the most direct exposure measure of the administered pdVWF/FVIII (1:1) concentrate, since it isolates the pdVWF/FVIII (1:1) contribution from endogenous activity. In patients with substantial endogenous activity, trough levels and AUCtotal become less useful for guiding treatment, as endogenous activity obscures the exogenous contribution these measures are meant to capture. Together, these insights support the opportunities individualization of prophylaxis using PK-guided dosing in VWD offers. Prospective studies linking PK metrics to bleeding outcomes are needed to establish evidence-based PK targets for prophylaxis in VWD, improving patient outcomes and well-being.
DISCLOSURES
Jelien den Hollander, PharmD: Octapharma - Research Funding; Octapharma - Consultancy (Includes expert testimony)